179 related articles for article (PubMed ID: 34006920)
1. A PROSS-designed extensively mutated estrogen receptor α variant displays enhanced thermal stability while retaining native allosteric regulation and structure.
Kriegel M; Wiederanders HJ; Alkhashrom S; Eichler J; Muller YA
Sci Rep; 2021 May; 11(1):10509. PubMed ID: 34006920
[TBL] [Abstract][Full Text] [Related]
2. Investigating the in Vitro Thermal Stability and Conformational Flexibility of Estrogen Receptors as Potential Key Factors of Their in Vivo Activity.
Le Grand A; André-Leroux G; Marteil G; Duval H; Sire O; Le Tilly V
Biochemistry; 2015 Jun; 54(25):3890-900. PubMed ID: 26029980
[TBL] [Abstract][Full Text] [Related]
3. Understanding the human estrogen receptor-alpha using targeted mutagenesis.
Skafar DF; Koide S
Mol Cell Endocrinol; 2006 Feb; 246(1-2):83-90. PubMed ID: 16442702
[TBL] [Abstract][Full Text] [Related]
4. Multidomain architecture of estrogen receptor reveals interfacial cross-talk between its DNA-binding and ligand-binding domains.
Huang W; Peng Y; Kiselar J; Zhao X; Albaqami A; Mendez D; Chen Y; Chakravarthy S; Gupta S; Ralston C; Kao HY; Chance MR; Yang S
Nat Commun; 2018 Aug; 9(1):3520. PubMed ID: 30166540
[TBL] [Abstract][Full Text] [Related]
5. Identification of regions within the F domain of the human estrogen receptor alpha that are important for modulating transactivation and protein-protein interactions.
Koide A; Zhao C; Naganuma M; Abrams J; Deighton-Collins S; Skafar DF; Koide S
Mol Endocrinol; 2007 Apr; 21(4):829-42. PubMed ID: 17185393
[TBL] [Abstract][Full Text] [Related]
6. Formation of a powerful capping motif corresponding to start of "helix 12" in agonist-bound estrogen receptor-alpha contributes to increased constitutive activity of the protein.
Skafar DF
Cell Biochem Biophys; 2000; 33(1):53-62. PubMed ID: 11322512
[TBL] [Abstract][Full Text] [Related]
7. Exploring interactions of endocrine-disrupting compounds with different conformations of the human estrogen receptor alpha ligand binding domain: a molecular docking study.
Celik L; Davey J; Lund D; Schiøtt B
Chem Res Toxicol; 2008 Nov; 21(11):2195-206. PubMed ID: 18921983
[TBL] [Abstract][Full Text] [Related]
8. Role of aspartate 351 in transactivation and active conformation of estrogen receptor alpha.
Kim JH; Lee MH; Kim BJ; Kim JH; Han SJ; Kim HY; Stallcup MR
J Mol Endocrinol; 2005 Dec; 35(3):449-64. PubMed ID: 16326832
[TBL] [Abstract][Full Text] [Related]
9. Charge clamps of lysines and hydrogen bonds play key roles in the mechanism to fix helix 12 in the agonist and antagonist positions of estrogen receptor α: intramolecular interactions studied by the ab initio fragment molecular orbital method.
Watanabe C; Fukuzawa K; Tanaka S; Aida-Hyugaji S
J Phys Chem B; 2014 May; 118(19):4993-5008. PubMed ID: 24725156
[TBL] [Abstract][Full Text] [Related]
10. Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains.
Métivier R; Penot G; Flouriot G; Pakdel F
Mol Endocrinol; 2001 Nov; 15(11):1953-70. PubMed ID: 11682626
[TBL] [Abstract][Full Text] [Related]
11. Targeted mutation of key residues at the start of helix 12 in the hERalpha ligand-binding domain identifies the role of hydrogen-bonding and hydrophobic interactions in the activity of the protein.
Zhao C; Abrams J; Skafar DF
J Steroid Biochem Mol Biol; 2006 Jan; 98(1):1-11. PubMed ID: 16191480
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs.
Nichols M; Cheng P; Liu Y; Kanterewicz B; Hershberger PA; McCarty KS
Breast Cancer Res Treat; 2010 Apr; 120(3):761-8. PubMed ID: 19526339
[TBL] [Abstract][Full Text] [Related]
13. In silico study of molecular mechanisms of action: Estrogenic disruptors among phthalate esters.
Zhu Q; Liu L; Zhou X; Ma M
Environ Pollut; 2019 Dec; 255(Pt 1):113193. PubMed ID: 31521998
[TBL] [Abstract][Full Text] [Related]
14. Estrogenicity of halogenated bisphenol A: in vitro and in silico investigations.
Zhang J; Li T; Wang T; Yuan C; Zhong S; Guan T; Li Z; Wang Y; Yu H; Luo Q; Wang Y; Zhang T
Arch Toxicol; 2018 Mar; 92(3):1215-1223. PubMed ID: 29152682
[TBL] [Abstract][Full Text] [Related]
15. Community-Wide Experimental Evaluation of the PROSS Stability-Design Method.
Peleg Y; Vincentelli R; Collins BM; Chen KE; Livingstone EK; Weeratunga S; Leneva N; Guo Q; Remans K; Perez K; Bjerga GEK; Larsen Ø; Vaněk O; Skořepa O; Jacquemin S; Poterszman A; Kjær S; Christodoulou E; Albeck S; Dym O; Ainbinder E; Unger T; Schuetz A; Matthes S; Bader M; de Marco A; Storici P; Semrau MS; Stolt-Bergner P; Aigner C; Suppmann S; Goldenzweig A; Fleishman SJ
J Mol Biol; 2021 Jun; 433(13):166964. PubMed ID: 33781758
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor α L543A,L544A mutation changes antagonists to agonists, correlating with the ligand binding domain dimerization associated with DNA binding activity.
Arao Y; Hamilton KJ; Coons LA; Korach KS
J Biol Chem; 2013 Jul; 288(29):21105-21116. PubMed ID: 23733188
[TBL] [Abstract][Full Text] [Related]
17. [Construction, Expression of hERα-LBD Prokaryotic Vector and the Activity of Expressed Protein].
Wang YF; Zhao JJ; Tian ZM; Guo YF
Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 48(1):61-65. PubMed ID: 28612560
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.
Fanning SW; Mayne CG; Dharmarajan V; Carlson KE; Martin TA; Novick SJ; Toy W; Green B; Panchamukhi S; Katzenellenbogen BS; Tajkhorshid E; Griffin PR; Shen Y; Chandarlapaty S; Katzenellenbogen JA; Greene GL
Elife; 2016 Feb; 5():. PubMed ID: 26836308
[TBL] [Abstract][Full Text] [Related]
19. A conserved surface on the ligand binding domain of nuclear receptors for allosteric control.
Buzón V; Carbó LR; Estruch SB; Fletterick RJ; Estébanez-Perpiñá E
Mol Cell Endocrinol; 2012 Jan; 348(2):394-402. PubMed ID: 21878368
[TBL] [Abstract][Full Text] [Related]
20. The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene.
Vajdos FF; Hoth LR; Geoghegan KF; Simons SP; LeMotte PK; Danley DE; Ammirati MJ; Pandit J
Protein Sci; 2007 May; 16(5):897-905. PubMed ID: 17456742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
